Cargando…
CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells
Natural killer (NK) cell immunotherapy has emerged as a novel treatment modality for various cancer types, including leukemia. The modulation of inhibitory signaling pathways in T cells and NK cells has been the subject of extensive investigation in both preclinical and clinical settings in recent y...
Autores principales: | Mohammadian Gol, Tahereh, Kim, Miso, Sinn, Ralph, Ureña-Bailén, Guillermo, Stegmeyer, Sarah, Gratz, Paul Gerhard, Zahedipour, Fatemeh, Roig-Merino, Alicia, Antony, Justin S., Mezger, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671270/ https://www.ncbi.nlm.nih.gov/pubmed/38003255 http://dx.doi.org/10.3390/ijms242216065 |
Ejemplares similares
-
CRISPR medicine for blood disorders: Progress and challenges in delivery
por: Mohammadian Gol, Tahereh, et al.
Publicado: (2023) -
Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing
por: Hou, Yujuan, et al.
Publicado: (2022) -
Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
por: Ureña-Bailén, Guillermo, et al.
Publicado: (2022) -
In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment
por: Grote, Stefan, et al.
Publicado: (2021) -
Somatic Reversion of a Novel IL2RG Mutation Resulting in Atypical X-Linked Combined Immunodeficiency
por: Hou, Yujuan, et al.
Publicado: (2021)